Showing 7081-7090 of 8690 results for "".
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- POWER Study Suggests EpiDuo plus Doxycycline May be an Alternative to Isotretinoinhttps://practicaldermatology.com/news/power-study-suggests-epiduo-plus-doxycycline-may-be-an-alternative-to-isotretinoin/2459000/Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) is an alternative to isotretinoin in patients intolerant to, or unable or unwilling to take, oral isotretinoin, and is an option for treatment of severe nodular acne, according to a new study. Findings suggest that th
- Envy Medical Appoints Chief Marketing Officer to Executive Teamhttps://practicaldermatology.com/news/envy-medical-appoints-chief-marketing-officer-to-executive-team/2459002/Envy Medical Products, Inc., appointed Shauna Lahiri to the newly created role of Chief Marketing Officer. Ms. Lahiri brings a 17-year record of building successful global marketing strategies, building and launching new brands achieving leadership in mas
- derma e® Introduces Scalp Relief Hair Carehttps://practicaldermatology.com/news/derma-e-introduces-scalp-relief-hair-care/2459006/derma e® launched its new Scalp Relief Shampoo and Conditioner. derma e® Scalp Relief Shampoo and Scalp Relief Conditioner work in four therapeutic ways to effectively target scalp problems. The shampoo is designed to cleanse, de-flake, soothe and nourish. The conditioner is designed to d
- Kythera Acquires Rights to Experimental Hair Loss Treatmenthttps://practicaldermatology.com/news/kythera-acquires-rights-to-experimental-hair-loss-treatment/2459008/Kythera Biopharmaceuticals has struck two separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a potential novel treatment of hair loss. In the agreement with Actelion, Kythera gained licensing of the worldwide rights to setipiprant, a clinical-stage se
- InMed Initiates Program Targeting Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-initiates-program-targeting-epidermolysis-bullosa-simplex/2459014/InMed Pharmaceuticals Inc. added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation, and inflammation that are signature characterist
- Galderma Launches Restylane Silk for Lip Enhancement and Treatment of Perioral Lineshttps://practicaldermatology.com/news/galderma-launches-restylane-silk-for-lip-enhancement-and-treatment-of-perioral-lines/2459015/Galderma launched Restylane® Silk, the first and only dermal filler FDA approved for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Restylane Silk is a smooth gel designed to restore natural youthful definitio
- derma e Launches Firming and Deep Wrinkle Productshttps://practicaldermatology.com/news/derma-e-launches-firming-and-deep-wrinkle-products/2459020/derma e® launched its new Firming DMAE Eye Lift and Deep Wrinkle Peptide Moisturizer SPF 30. “derma e® is raising the bar for natural skin care performance with the launch of these two new products,” says Jennifer Norman, Vice President of Marketing for derma e®. &
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- BioD Receives US Patent for Placental Tissue Technology for Improved Wound Care and Healinghttps://practicaldermatology.com/news/biod-receives-us-patent-for-placental-tissue-technology-for-improved-wound-care-and-healing/2459024/BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable T